Loading clinical trials...
Loading clinical trials...
A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis
The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.
The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following multiple-dose administration of the two different dosing regimens that are being evaluated in the Phase 3 RMS studies.
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
Breastlink Medical Group, Inc.
Long Beach, California, United States
Multiple Sclerosis Center at UCSF
San Francisco, California, United States
Raleigh Neurology Associates PA
Raleigh, North Carolina, United States
Neurology and Neuroscience Associates Inc.
Akron, Ohio, United States
Hope Neurology MS Center
Knoxville, Tennessee, United States
Central Texas Neurology Consultants PA
Round Rock, Texas, United States
Start Date
June 23, 2016
Primary Completion Date
October 20, 2017
Completion Date
October 20, 2017
Last Updated
March 27, 2018
22
ACTUAL participants
RPC1063
DRUG
Lead Sponsor
Celgene
NCT06276634
NCT07225504
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06809192